Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Terns Pharmaceuticals ( (TERN) ) has shared an update.
On December 8, 2025, Terns Pharmaceuticals announced updated data from the Phase 1 CARDINAL trial of TERN-701, presented at the 67th American Society of Hematology Annual Meeting. The trial, which involves patients with previously treated chronic myeloid leukemia, showed promising results with a 74% major molecular response (MMR) rate by 24 weeks across all dose cohorts and a 75% MMR rate at doses above 320 mg. The trial’s safety profile was encouraging, with no dose-limiting toxicities observed, supporting the selection of 320 mg and 500 mg as recommended doses for phase 2. These findings reinforce TERN-701’s potential as a best-in-disease therapy, with plans to advance into pivotal Phase 3 trials in 2026.
The most recent analyst rating on (TERN) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Terns Pharmaceuticals stock, see the TERN Stock Forecast page.
Spark’s Take on TERN Stock
According to Spark, TipRanks’ AI Analyst, TERN is a Neutral.
Terns Pharmaceuticals’ overall score reflects significant financial challenges due to lack of revenue and ongoing losses. Despite strong cash reserves and low debt, the company faces high risk due to persistent cash burn. The stock’s technical indicators suggest a bearish trend, and its negative valuation factors further hinder attractiveness. However, the new CFO appointment could enhance strategic financial management, offering a glimmer of potential improvement.
To see Spark’s full report on TERN stock, click here.
More about Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing novel therapies for cancer treatment. The company’s primary product, TERN-701, is an investigational allosteric BCR::ABL1 inhibitor aimed at treating chronic myeloid leukemia (CML), with a market focus on second-line-plus (2L+) and first-line (1L) CML treatment settings.
Average Trading Volume: 2,904,262
Technical Sentiment Signal: Buy
Current Market Cap: $2.64B
See more data about TERN stock on TipRanks’ Stock Analysis page.